Company · RTSN
Retension Pharmaceuticals, Inc.
Nasdaq's symbol directory lists RTSN on Nasdaq as “Retension Pharmaceuticals, Inc. - Common Stock”.
In the 12 months to Nov 8, 2026: insiders bought on 2 occasions ($370K); 4 filings by holders of 5% or more; 2 company reports (Form 8-K, since May 26, 2026).
All insider filings at the SEC · Appeared in No. 25, No. 24, No. 23, No. 22, No. 21
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Keller Eric L., CHIEF EXECUTIVE OFFICER bought $250K
- Franklin M. Berger bought $120K
Every trade (2)
- BUYKeller Eric L., CHIEF EXECUTIVE OFFICER bought $250K
- BUYFranklin M. Berger bought $120K
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- The B Group, Inc. 10%
- PVG ASSET MANAGEMENT CORP 8.3%
- Laurence W. Lytton 7.4%
- Eric Keller 7.07%
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Departure or appointment of directors or officers Oct 23, 2026
- Amendments to articles or bylaws; change in fiscal year Oct 13, 2026
Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.